Ancient viral leftovers in your DNA are waking up — and that may be aging you
Nearly half of the human genome consists of remnants from ancient viral infections. In youth, cells keep these sequences locked down. As we age, the locks weaken.
Transposons — sometimes called jumping genes — are DNA sequences capable of copying themselves and inserting those copies elsewhere in the genome. Most have been immobilized over millions of years of evolution, silenced by the cell’s own molecular machinery. But they haven’t disappeared. By some estimates they make up around 45 percent of the human genome. That’s not a rounding error.
In young, healthy cells, transposons are suppressed through epigenetic silencing — a system of chemical tags on the DNA that effectively lock these sequences in place. With age, those mechanisms deteriorate. The locks open. Transposons become more active, generate copies of themselves, and in doing so leave behind molecular debris that triggers immune responses and fuels chronic inflammation.
The evidence in humans is starting to accumulate
What was long a compelling theory is now gaining empirical traction. A recent analysis of human data finds that stronger suppression of transposon activity correlates with lower biological age scores — measures that assess not calendar age but the actual state of the genome and its epigenetic clocks. In short: people with quieter transposons appear biologically younger.
This doesn’t prove causality. It’s possible that healthier cells are simply better at suppressing transposons, rather than suppression causing youth. But the direction of the association is consistent with animal experiments. In mice where transposon activity was artificially elevated, aging accelerated visibly. Where it was suppressed, aging slowed.
An old HIV drug as an anti-aging treatment?
The longevity field’s interest in transposons is growing partly because they appear to connect multiple aging processes. Transposon activity tracks with DNA damage, telomere shortening, and — again — inflammaging. That makes them an appealing target: silencing transposons might address several aging mechanisms simultaneously.
One class of drugs already exists that does exactly this: reverse transcriptase inhibitors, originally developed to fight HIV and other retroviruses. They block the specific step by which transposons copy themselves. Animal studies have produced promising results. Whether they’re safe and effective in humans as an anti-aging intervention is entirely unknown. The path from laboratory finding to clinical use is long, and the risks of chronically interfering with such fundamental genomic processes remain poorly mapped.